<p>Lonapegsomatropin Ascendis Pharma is a medicine that is used to improve growth in children and adolescents who do not produce enough growth hormone (growth hormone deficiency or GHD). The medicine is intended for children and adolescents from 3 up to 18 years of age.</p><p>GHD is rare, and Lonapegsomatropin Ascendis Pharma was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 October 2019. Further information on the orphan designation can be found here: <a href="/en/medicines/human/orphan-designations/eu-3-19-2213" data-entity-type="node" data-entity-uuid="ec922cf7-da1a-4663-9b8e-7b738358000c" data-entity-substitution="canonical">ema.europa.eu/medicines/human/orphan-designations/eu3192213</a>.</p><p>Lonapegsomatropin Ascendis Pharma contains the active substance lonapegsomatropin.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])</p> </div>
Therapeutic Area (MeSH)
ATC Code
H01AC09
ATC Item
N/A
Pharmacotherapeutic Group
Pituitary and hypothalamic hormones and analogues
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Lonapegsomatropin | N/A | Lonapegsomatropin |
EMA Name
Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
Medicine Name
Skytrofa (previously Lonapegsomatropin Ascendis Pharma)
Aliases
N/ANo risk management plan link.
